Aveo Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, AVEO, Aveo Pharmaceuticals Inc, priceseries

Aveo Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
3.27
Close
3.32
High
3.40
Low
3.25
Previous Close
3.24
Daily Price Gain
0.08
YTD High
5.34
YTD High Date
Jan 3, 2022
YTD Low
3.06
YTD Low Date
Jan 28, 2022
YTD Price Change
-1.95
YTD Gain
-37.00%
52 Week High
18.24
52 Week High Date
Mar 11, 2021
52 Week Low
3.06
52 Week Low Date
Jan 28, 2022
52 Week Price Change
-4.58
52 Week Gain
-57.97%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 3. 2017
6.03
Jan 10. 2017
6.34
5 Trading Days
5.03%
Link
LONG
Feb 10. 2017
6.41
Mar 14. 2017
8.52
21 Trading Days
32.95%
Link
LONG
Jun 22. 2017
7.28
Jul 17. 2017
25.00
16 Trading Days
243.45%
Link
LONG
Aug 21. 2018
23.70
Sep 6. 2018
26.99
11 Trading Days
13.86%
Link
LONG
Mar 29. 2019
8.20
Apr 4. 2019
9.43
4 Trading Days
14.93%
Link
LONG
Sep 9. 2019
7.07
Sep 25. 2019
9.12
12 Trading Days
29.06%
Link
LONG
Mar 25. 2020
3.04
Apr 3. 2020
3.55
7 Trading Days
16.83%
Link
LONG
Apr 29. 2020
5.20
May 27. 2020
8.19
19 Trading Days
57.47%
Link
LONG
Dec 30. 2020
5.72
Jan 25. 2021
7.76
16 Trading Days
35.65%
Link
LONG
Mar 10. 2021
15.28
Mar 11. 2021
16.76
1 Trading Days
9.69%
Link
LONG
Aug 5. 2021
5.50
Aug 17. 2021
5.84
8 Trading Days
6.21%
Link
LONG
Aug 23. 2021
5.92
Sep 3. 2021
6.25
9 Trading Days
5.53%
Link
Company Information
Stock Symbol
AVEO
Exchange
NasdaqCM
Company URL
http://www.aveooncology.com
Company Phone
617- 531-2130
CEO
Michael P. Bailey
Headquarters
Massachusetts
Business Address
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE, MA 02142
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001325879
About

AVEO Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in the advancement of therapeutics for oncology and other areas of unmet medical need. Its products include Tivozanib, Ficlatuzmab, AV-203, AV-380, and AV-353. It focuses on the development of its lead candidate, Tivozanib, in North America as a treatment for renal cell carcinoma and other cancers. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

Description

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company's pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension. The company has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading